Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists

Magdolna Kovács, Andrew V Schally, József L. Varga, Márta Zarándi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Potent antagonists of growth hormone-releasing hormone (GHRH) have been developed for the treatment of disorders caused by excessive GHRH or growth hormone (GH) production and or therapy of cancers. GHRH antagonists suppressed the release of GH and insulin-like growth factor (IGF)-I in transgenic mice overexpressing human (h) GHRH gene, an animal model of human acromegaly. It was also shown in GH3 rat pituitary tumor cells overexpressing the human pituitary GHRH receptor (pGHRH-R) that GHRH antagonists can inhibit c-AMP production and GH secretion through the human receptor. These observations indicate that GHRH antagonists could be used clinically in disorders characterized by excessive GHRH/GH secretion. Many recent studies demonstrate that GHRH antagonists can inhibit tumor growth by several mechanisms. By indirect action through pGHRH-Rs these antagonists suppress circulating GH/IGF-I level, which results in the inhibition of cancers that depend on GH and/or IGF-I as growth factors. However, GHRH antagonists are also effective inhibitors of tumor IGF-II production, which is a potent mitogen but independent of GH. GHRH antagonists can inhibit tumor cell proliferation by direct action on tumor cell receptors, suppressing the IGF-II and other growth factor production of tumor cells. In addition, various human tumors and tumor cell lines secrete GHRH peptide and respond to GHRH with proliferation. This finding suggests that GHRH functions as an autocrine growth factor and that GHRH antagonists can block its effects on tumor growth. Recently, we demonstrated the expression of hGHRH-R and its splice variants in various human cancers. Antiprofiferative action of GHRH antagonists on these cancers indicates that the direct inhibitory effects of GHRH antagonists are mediated by tumoral GHRH receptors.

Original languageEnglish
Pages (from-to)314-321
Number of pages8
JournalCurrent Medicinal Chemistry
Volume15
Issue number4
DOIs
StatePublished - Feb 1 2008

Fingerprint

Hormone Antagonists
Growth Hormone-Releasing Hormone
Antineoplastic Agents
Tumors
Growth Hormone
Neoplasms
Insulin-Like Growth Factor I
Cells
Intercellular Signaling Peptides and Proteins
Insulin-Like Growth Factor II
Human Growth Hormone
Pituitary Hormone-Regulating Hormone Receptors
IGF Type 2 Receptor
Acromegaly
Cell proliferation
Pituitary Neoplasms

Keywords

  • Antagonistic analogs
  • Anti-cancer
  • Cell proliferation
  • Growth hormone (GH)
  • Inhibition
  • Insulin like growth factor (IGF)
  • Oncogene
  • Tumor growth

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. / Kovács, Magdolna; Schally, Andrew V; Varga, József L.; Zarándi, Márta.

In: Current Medicinal Chemistry, Vol. 15, No. 4, 01.02.2008, p. 314-321.

Research output: Contribution to journalArticle

Kovács, Magdolna ; Schally, Andrew V ; Varga, József L. ; Zarándi, Márta. / Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. In: Current Medicinal Chemistry. 2008 ; Vol. 15, No. 4. pp. 314-321.
@article{82fd092d23e2464f9aa570bd88fc042e,
title = "Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists",
abstract = "Potent antagonists of growth hormone-releasing hormone (GHRH) have been developed for the treatment of disorders caused by excessive GHRH or growth hormone (GH) production and or therapy of cancers. GHRH antagonists suppressed the release of GH and insulin-like growth factor (IGF)-I in transgenic mice overexpressing human (h) GHRH gene, an animal model of human acromegaly. It was also shown in GH3 rat pituitary tumor cells overexpressing the human pituitary GHRH receptor (pGHRH-R) that GHRH antagonists can inhibit c-AMP production and GH secretion through the human receptor. These observations indicate that GHRH antagonists could be used clinically in disorders characterized by excessive GHRH/GH secretion. Many recent studies demonstrate that GHRH antagonists can inhibit tumor growth by several mechanisms. By indirect action through pGHRH-Rs these antagonists suppress circulating GH/IGF-I level, which results in the inhibition of cancers that depend on GH and/or IGF-I as growth factors. However, GHRH antagonists are also effective inhibitors of tumor IGF-II production, which is a potent mitogen but independent of GH. GHRH antagonists can inhibit tumor cell proliferation by direct action on tumor cell receptors, suppressing the IGF-II and other growth factor production of tumor cells. In addition, various human tumors and tumor cell lines secrete GHRH peptide and respond to GHRH with proliferation. This finding suggests that GHRH functions as an autocrine growth factor and that GHRH antagonists can block its effects on tumor growth. Recently, we demonstrated the expression of hGHRH-R and its splice variants in various human cancers. Antiprofiferative action of GHRH antagonists on these cancers indicates that the direct inhibitory effects of GHRH antagonists are mediated by tumoral GHRH receptors.",
keywords = "Antagonistic analogs, Anti-cancer, Cell proliferation, Growth hormone (GH), Inhibition, Insulin like growth factor (IGF), Oncogene, Tumor growth",
author = "Magdolna Kov{\'a}cs and Schally, {Andrew V} and Varga, {J{\'o}zsef L.} and M{\'a}rta Zar{\'a}ndi",
year = "2008",
month = "2",
day = "1",
doi = "10.2174/092986708783497355",
language = "English",
volume = "15",
pages = "314--321",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists

AU - Kovács, Magdolna

AU - Schally, Andrew V

AU - Varga, József L.

AU - Zarándi, Márta

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Potent antagonists of growth hormone-releasing hormone (GHRH) have been developed for the treatment of disorders caused by excessive GHRH or growth hormone (GH) production and or therapy of cancers. GHRH antagonists suppressed the release of GH and insulin-like growth factor (IGF)-I in transgenic mice overexpressing human (h) GHRH gene, an animal model of human acromegaly. It was also shown in GH3 rat pituitary tumor cells overexpressing the human pituitary GHRH receptor (pGHRH-R) that GHRH antagonists can inhibit c-AMP production and GH secretion through the human receptor. These observations indicate that GHRH antagonists could be used clinically in disorders characterized by excessive GHRH/GH secretion. Many recent studies demonstrate that GHRH antagonists can inhibit tumor growth by several mechanisms. By indirect action through pGHRH-Rs these antagonists suppress circulating GH/IGF-I level, which results in the inhibition of cancers that depend on GH and/or IGF-I as growth factors. However, GHRH antagonists are also effective inhibitors of tumor IGF-II production, which is a potent mitogen but independent of GH. GHRH antagonists can inhibit tumor cell proliferation by direct action on tumor cell receptors, suppressing the IGF-II and other growth factor production of tumor cells. In addition, various human tumors and tumor cell lines secrete GHRH peptide and respond to GHRH with proliferation. This finding suggests that GHRH functions as an autocrine growth factor and that GHRH antagonists can block its effects on tumor growth. Recently, we demonstrated the expression of hGHRH-R and its splice variants in various human cancers. Antiprofiferative action of GHRH antagonists on these cancers indicates that the direct inhibitory effects of GHRH antagonists are mediated by tumoral GHRH receptors.

AB - Potent antagonists of growth hormone-releasing hormone (GHRH) have been developed for the treatment of disorders caused by excessive GHRH or growth hormone (GH) production and or therapy of cancers. GHRH antagonists suppressed the release of GH and insulin-like growth factor (IGF)-I in transgenic mice overexpressing human (h) GHRH gene, an animal model of human acromegaly. It was also shown in GH3 rat pituitary tumor cells overexpressing the human pituitary GHRH receptor (pGHRH-R) that GHRH antagonists can inhibit c-AMP production and GH secretion through the human receptor. These observations indicate that GHRH antagonists could be used clinically in disorders characterized by excessive GHRH/GH secretion. Many recent studies demonstrate that GHRH antagonists can inhibit tumor growth by several mechanisms. By indirect action through pGHRH-Rs these antagonists suppress circulating GH/IGF-I level, which results in the inhibition of cancers that depend on GH and/or IGF-I as growth factors. However, GHRH antagonists are also effective inhibitors of tumor IGF-II production, which is a potent mitogen but independent of GH. GHRH antagonists can inhibit tumor cell proliferation by direct action on tumor cell receptors, suppressing the IGF-II and other growth factor production of tumor cells. In addition, various human tumors and tumor cell lines secrete GHRH peptide and respond to GHRH with proliferation. This finding suggests that GHRH functions as an autocrine growth factor and that GHRH antagonists can block its effects on tumor growth. Recently, we demonstrated the expression of hGHRH-R and its splice variants in various human cancers. Antiprofiferative action of GHRH antagonists on these cancers indicates that the direct inhibitory effects of GHRH antagonists are mediated by tumoral GHRH receptors.

KW - Antagonistic analogs

KW - Anti-cancer

KW - Cell proliferation

KW - Growth hormone (GH)

KW - Inhibition

KW - Insulin like growth factor (IGF)

KW - Oncogene

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=39449110906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449110906&partnerID=8YFLogxK

U2 - 10.2174/092986708783497355

DO - 10.2174/092986708783497355

M3 - Article

VL - 15

SP - 314

EP - 321

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 4

ER -